SPECIALTY QUANTITY LIMIT PROGRAM

GLEEVEC (imatinib mesylate)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Gleevec (imatinib mesylate) 100 mg tablet	90 tablets per 30 days	Ph+ CML • Adults with CP: 400 mg orally daily • Adults with AP or BC: 600 mg orally daily • Pediatrics with CP: 340 mg/m²/day (not to exceed 600 mg)
		Ph+ ALL • Adults: 600 mg orally daily • Pediatrics: 340 mg/m²/day (not to exceed 600 mg)
Gleevec (imatinib mesylate) 400 mg tablet	60 tablets per 30 days	MDS/MPD: 400 mg orally daily
		ASM: 100 mg or/to 400 mg orally daily
		HES/CEL: 100 mg or/to 400 mg orally daily
		DFSP: 400 mg orally twice a day
		Metastatic and/or unresectable GIST: 400 mg orally daily up to 400 mg twice daily
		Adjuvant treatment of GIST: 400 mg orally daily

The limits may apply to the generic equivalent medication.

III. REFERENCES

- 1. Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2018.
- 2. imatinib [package insert]. Cranbury, NJ: Sun Pharmaceuticals Inc.; November 2018.

Specialty Quantity Limit imatinib-Gleevec 1719-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



^{*} ALL: acute lymphoblastic leukemia; ASM: aggressive systemic mastocytosis; CML: chronic myeloid leukemia; CML-AP: advanced phase; CML-CP: chronic phase; CML-BC-blast crisis; DFSP: dermatofibrosarcoma protuberans; GIST: gastrointestinal stromal tumors; HES/CEL: hypereosinophilic syndrome/chronic eosinophilic leukemia; MDS/MPD: myelodysplastic/myeloproliferative diseases; Ph+: Philadelphia chromosome positive